chloroquine has been researched along with lovastatin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Behnam, MA; Boldescu, V; Klein, CD; Nitsche, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Iwaki, T; Noguchi, A; Sekimoto, T | 1 |
| Albers, JJ; Bierman, EL; Cheung, MC; Oram, JF | 1 |
| Duan, H; Lange, Y; Mazzone, T | 1 |
| Assis, EF; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; d'Avila, JC; da Silva, TI; Estato, V; Reis, PA; Siqueira, LD; Tibiriça, EV; Zimmerman, GA | 1 |
| Marceau, F; Parks, A | 1 |
| Al-Ashmawy, GM; Amr, EA; El-Ashmawy, NE; Khedr, EG | 1 |
| Chen, JH; Du, JJ; Huang, JJ; Huang, XM; Huang, Z; Lin, QY; Lin, WJ; Long, Z; Ma, WZ; Qin, X; Shen, YF; Yang, Y; Zhang, N; Zheng, BW; Zhong, FF | 1 |
2 review(s) available for chloroquine and lovastatin
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for chloroquine and lovastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Sources of extramitochondrial corticoidogenic cholesterol in the adrenal cortex.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Calcium; Cattle; Chloroquine; Cholesterol; Cricetinae; Cycloheximide; Dichlorvos; Female; In Vitro Techniques; Lovastatin; Male; Mesocricetus; Naphthalenes; Rats; Rats, Inbred Strains; Species Specificity; Sulfonamides | 1985 |
The effects of subfractions of high density lipoprotein on cholesterol efflux from cultured fibroblasts. Regulation of low density lipoprotein receptor activity.
Topics: Anticholesteremic Agents; Chloroquine; Cholesterol; Fibroblasts; Humans; Kinetics; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Naphthalenes; Receptors, Cell Surface; Receptors, LDL; Skin; Structure-Activity Relationship | 1981 |
Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci.
Topics: 3T3 Cells; Animals; Anticholesteremic Agents; Chloramphenicol O-Acetyltransferase; Chloroquine; Cholesterol; Dactinomycin; Estradiol; Gene Expression Regulation; Homeostasis; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Monensin; Protein Processing, Post-Translational; Receptors, LDL; RNA, Messenger; Surface-Active Agents; Transcription, Genetic | 1996 |
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.
Topics: Animals; Brain; CD11b Antigen; Chemokines; Chloroquine; Cognition Disorders; Cytokines; Edema; Endothelium; Heme Oxygenase-1; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; Malaria, Cerebral; Membrane Proteins; Mice; Mice, Inbred C57BL; Oxidative Stress; Plasmodium berghei; RNA, Messenger | 2012 |
Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.
Topics: Amiodarone; Anticholesteremic Agents; Autophagy; beta-Cyclodextrins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chloroquine; Cholesterol; Cytostatic Agents; Cytotoxins; Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Lidocaine; Lovastatin; Lysosomes; Microtubule-Associated Proteins; Poly (ADP-Ribose) Polymerase-1; Procainamide; Quinacrine | 2016 |
Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Chloroquine; Docosahexaenoic Acids; Female; Humans; Lovastatin; Transforming Growth Factor beta1; Triple Negative Breast Neoplasms | 2020 |
Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin.
Topics: Animals; Antimetabolites; Autophagy; Cell Survival; Chloroquine; Colorectal Neoplasms; Deoxyglucose; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HCT116 Cells; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2021 |